Table A1.

Pathogen–antimicrobial combinations for national AMR surveillance (GLASS).

Pathogen	Antimicrobial Class	Antimicrobial Agents Used for AST ‡
S. pneumoniae	Penicillins	Penicillin G
	Sulfonamides and trimethoprim	Co-trimoxazole
	Third-generation cephalosporins	Ceftriaxone
Staphylococcus aureus	Penicillinase-stable beta-lactams	Cefoxitin b and Oxacillin a
Escherichia coli	Sulfonamides and trimethoprim	Co-trimoxazole
	Fluoroquinolones	Ciprofloxacin
	Third-generation cephalosporins	Ceftriaxone and ceftazidime
	Fourth-generation cephalosporins	Cefepime
	Carbapenems	Meropenem
	Polymyxins	Colistin c
	Penicillins	Ampicillin
Klebsiella species	Sulfonamides and trimethoprim	Co-trimoxazole
	Fluoroquinolones	Ciprofloxacin
	Third-generation cephalosporins	Ceftriaxone and ceftazidime
	Fourth-generation cephalosporins	Cefepime
	Carbapenems	Meropenem
	Polymyxins	Colistin c
Acinetobacter species	Tetracyclines	Tigecycline
	Aminoglycosides	Gentamicin and Amikacin
	Carbapenems *	Meropenem
	Polymyxins	Colistin c
Pseudomonous Aeruginosa	Carbapenems	Meropenem
Salmonella spp.	Fluoroquinolones	Ciprofloxacin
	Third-generation cephalosporins	Ceftriaxone and ceftazidime
	Carbapenems *	Meropenem

Key:^‡ The listed antimicrobials are priorities for surveillance of resistance in each pathogen, although they may not be first-line options for treatment. One or more of the drugs listed may be tested. ^a Oxacillin is a surrogate for testing reduced susceptibility or resistance to penicillin; the AST report to clinicians should state reduced susceptibility or resistance to penicillin. ^b Cefoxitin is a surrogate for testing susceptibility to oxacillin (methicillin, nafcillin); the AST report to clinicians should state susceptibility or resistance to oxacillin. ^c Minimum inhibitory concentration (MIC). * Imipenem or meropenem is preferred to represent the group when available.